GEN-MKT-18-7897-A
Mar 3, 2017 | Blogs, Forensic | 0 comments
Working in a forensic lab means technicians want super high-quality data in ultra-fast time. Yet, how do you go about detecting an unlimited number of analytes without re-injecting the sample all while new targeted compounds are being added to the screened panel? In the following application note, “Ultra-Fast Forensic Toxicological Screening and Quantitation in Under 3 Minutes Using SCIEX X500R QTOF System and SCIEX OS 1.0 Software,” researchers set out to achieve a fast method that could detect an unlimited number of analytes with all information afforded mass accuracy, LC retention time, and MS/MS spectral library matching.
Perhaps you have encountered a situation in which an aging sample contains compounds, yet they have degraded and are no longer detectable. Moments like these were front and center on the minds of our researchers as they went about their analysis and knowing that high-speed data processing and straightforward sample preparation are key to a lab’s productivity without the need to reanalyze, they got to work. Using the X500R system with its Time of Flight (TOF) technology, they found that modern QTOF systems provide the capability of switching between MS and MS/MS scans instantly, enabling rapid obtainments of structural information.
Want to know more? Discover how the researchers optimized conditions and extended LC runtime using different columns than previous methods, for better retention of polar species. Source parameters, system settings, chromatograms, and identifying results are all depicted within this application note. However, the biggest take away our researchers want to convey is that SWATH® Acquisition makes it, so all detectable data is captured at once, so there is no need to reanalyze the sample down the line.
For research use only. Not for use in diagnostic procedures.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network